

Publication

Quantitative contribution of efflux to multi-drug resistance of clinical *Escherichia coli* and *Pseudomonas aeruginosa* strains

JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

ID 4515716

Author(s) Cunrath, Olivier; Meinel, Dominik M.; Maturana, Pauline; Fanous, Joseph; Buyck, Julien M.; Saint Auguste, Pamela; Seth-Smith, Helena M. B.; Körner, Jonas; Dehio, Christoph; Trebosc, Vincent; Kemmer, Christian; Neher, Richard; Egli, Adrian; Bumann, Dirk

Author(s) at UniBasel [Neher, Richard](#) ; [Dehio, Christoph](#) ; [Bumann, Dirk](#) ;

Year 2019

Title Quantitative contribution of efflux to multi-drug resistance of clinical *Escherichia coli* and *Pseudomonas aeruginosa* strains

Journal EBioMedicine

Volume 41

Pages / Article-Number 479-487

Keywords Antibiotic resistance; Clinical strains; Efflux; Genetic engineering

Mesh terms Anti-Bacterial Agents, pharmacology; Bacteremia, microbiology, pathology; Bacterial Outer Membrane Proteins, genetics; Drug Resistance, Multiple, Bacterial, genetics; *Escherichia coli*, drug effects, genetics, isolation & purification; *Escherichia coli* Proteins, genetics; Gene Deletion; Humans; Membrane Transport Proteins, genetics; Microbial Sensitivity Tests; *Pseudomonas aeruginosa*, drug effects, genetics, isolation & purification; Whole Genome Sequencing

Efflux pumps mediate antimicrobial resistance in several WHO critical priority bacterial pathogens. However, most available data come from laboratory strains. The quantitative relevance of efflux in more relevant clinical isolates remains largely unknown.; We developed a versatile method for genetic engineering in multi-drug resistant (MDR) bacteria, and used this method to delete *tolC* and specific antibiotic-resistance genes in 18 representative MDR clinical *E. coli* isolates. We determined efflux activity and minimal inhibitory concentrations for a diverse set of clinically relevant antibiotics in these mutants. We also deleted *oprM* in MDR *P. aeruginosa* strains and determined the impact on antibiotic susceptibility.; *tolC* deletion abolished detectable efflux activity in 15 out of 18 tested *E. coli* strains, and modulated antibiotic susceptibility in many strains. However, all mutant strains retained MDR status, primarily because of other, antibiotic-specific resistance genes. Deletion of *oprM* altered antibiotic susceptibility in a fraction of clinical *P. aeruginosa* isolates.; Efflux modulates antibiotic resistance in clinical MDR isolates of *E. coli* and *P. aeruginosa*. However, when other antimicrobial-resistance mechanisms are present, inhibition of MDR efflux pumps alone is often not sufficient to restore full susceptibility even for antibiotics with a dramatic impact of efflux in laboratory strains. We propose that development of novel antibiotics should include target validation in clinical MDR isolates. FUND: Innovative Medicines Initiative of European Union and EFPIA, Schweizerischer Nationalfonds, Swiss National Research Program 72, EU Marie Skłodowska-Curie program. The funders played no role in design, data collection, data analysis, interpretation, writing of the report, and in the decision to submit the paper for publication.

Publisher Elsevier

ISSN/ISBN 2352-3964

edoc-URL <https://edoc.unibas.ch/72440/>

Full Text on edoc Available;

Digital Object Identifier DOI 10.1016/j.ebiom.2019.02.061

PubMed ID <http://www.ncbi.nlm.nih.gov/pubmed/30852163>

ISI-Number 000464321900061

Document type (ISI) Journal Article